SPOTLIGHT: FDA demands delay Genzyme approval
Genzyme has been handed a letter from the FDA spelling out a new set of demands for data on Synvisc-One, a new version of its osteoarthritis drug that is dosed at twice a year. Genzyme says the agency's demands will delay an approval until the second half of next year. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
